Thioredoxin-interacting protein: a new potential target for diabetes and related vascular complications therapy.
- Author:
Ping WU
;
Guan-hua DU
- Publication Type:Journal Article
- MeSH:
Apoptosis;
Carrier Proteins;
metabolism;
Diabetes Complications;
drug therapy;
metabolism;
Diabetes Mellitus;
drug therapy;
metabolism;
Endothelial Cells;
pathology;
Humans;
Inflammation;
Insulin Resistance;
Insulin-Secreting Cells;
pathology;
Vascular Diseases;
drug therapy;
metabolism
- From:
Acta Pharmaceutica Sinica
2015;50(12):1559-1564
- CountryChina
- Language:Chinese
-
Abstract:
Thioredoxin-interacting protein (TXNIP), also known as vitamin D3-up-regulated protein (VDUP1), is an endogenous inhibitor of thioredoxin (Trx), which regulates the cellular reduction-oxidation (redox) state. TXNIP regulates cellular survival, apoptosis and inflammation induced by glucotoxicity, heat shock and mechanical pressure. The above functions of TXNIP are regulated by carbohydrate response element binding protein (ChREBP) and AMP-dependent protein kinase (AMPK). In recent years, numerous studies showed that TXNIP is involved in diabetes and diabetic complications. On the one hand, TXNIP functions in diabetes by increasing insulin resistance and hepatic gluconeogenesis. TXNIP expression is induced by high glucose, which is implicated in pancreatic beta cell glucotoxicity and endothelial cells dysfunction. TXNIP may contribute to the development and progression of diabetes and its vascular complications. TXNIP may be a new target for diabetes and its vascular complications therapy.
